Scientists at Johns Hopkins University are learning how to treat various diseases and injuries with the endogenous adult stem cells that naturally exist within each person’s own body. Under the direction of Dr. Jennifer Elisseef, associate professor in the deparment of biomedical engineering at Johns Hopkins, a number of therapies have already been developed and are currently being tested in clinical trials.

Dr. Elisseef’s lab focuses primarily on the stimulation of endogenous adult stem cells, rather than on the administration of adult stem cells derived from outside sources. As she explains, "It’s going to be cheaper and easier to deliver to patients. We wanted something off-the-shelf, that the surgeon can grab when he needs it."

The first condition for which Dr. Elisseef and her colleagues developed a new type of therapy was damaged knee cartilage – an increasingly common malady among the general public. The scientists found that there is no need to administer adult stem cells from an outside source when there are plenty of adult stem cells residing within each person’s own body, and which exist solely for the purpose of regenerating damaged tissue – although it was only recently that researchers have discovered how to stimulate and utilize these endogenous adult stem cells. Now, with the specific therapy that Dr. Elisseef and her colleagues have developed, patient improvement is rapid and dramatic. According to Dr. Elisseef, "And their function is better. They might not be star athletes, but they can go out and do something like play doubles tennis."

The scientists focused specifically on the holes that develop in knees when a piece of knee cartilage is damaged or missing altogether. Referring to them as "potholes", Dr. Elisseef explained that, "It will gradually get bigger and bigger, and you get a generalized arthritic process happening in the joint. You really want to treat them when they’re a reasonable size." The current, conventional medical treatment, known as "micro-fracture", involves surgically "tapping into" the surrounding bone, from which blood and marrow that are rich in mesenchymal stem cells are allowed to "ooze out", thereby repairing the holes, at least theoretically. In actuality, however, as Dr. Elisseef describes, "The problem is, it ends up making more scar tissue instead of the real cartilage, and it doesn’t fully fill the defects." In a new approach, her lab began developing a hydrogel which they derived from bovine cartilage and which serves as a matrix on which the human body’s endogenous stem cells can grow. After being solidified with ultraviolet light, the hydrogel is attached to the injured cartilage with a type of "glue" that was also developed in Dr. Elisseef’s lab, into which the porous material is allowed to absorb the stem cells from the blood and bone marrow that are released from the micro-fractures. Within a few months, the endogenous stem cells have formed new cartilage. In the first clinical trial – which was conducted in Europe in order to take advantage of lower costs and fewer regulatory hurdles – 15 adults were treated with this therapy, in whom 89% of cartilage defects were found to have healed after a year, which is a significant improvement over the 50% response rate that is found with the conventional treatment.

Dr. Elisseef’s lab is also testing a number of other therapies based upon endogenous adult stem cells, which include a new type of contact lens that can guide the patient’s endogenous stem cells to rebuild damaged corneal tissue, for which she has received a five-year, $4 million U.S. Department of Defense grant that was just awarded this week. As she explains, "Someone’s stable now. They’re in the hospital and have a corneal injury. How can we repair that? How can we rebuild that cornea? We’re hoping that, working with the Deparment of Defense, these people who really have a strong need for this will help move the technology forward." Preliminary studies on rabbits have shown encouraging results.

Her laboratory is also currently involved in the development of a new biomaterial that can be shaped and contoured with beams of light, which she is developing in collaboration with the California-based company Kythera, and which is expected to be useful in reconstructing lost tissue such as from combat injuries or breast lumpectomies. According to Dr. Elisseef, "We make it from fat tissue. We take the fat and process it with chemicals. We take out the cells. We don’t want any foreign DNA in there. And we take out the lipids." What remains is just the connective tissue scaffolding of collagen and proteins, on which the endogenous stem cells can grow and regenerate new tissue.

As Dr. Elisseef further adds, "People are working on the basic science of things and trying to understand how tissue develops but also at the same time developing practical technologies that can be used in the clinic today."

According to Dr. Barley Griffeth, chief of cardiac surgery at the University of Maryland Medical Center, whose own research focuses on the regeneration of cardiac muscle, "A cell in free space doesn’t know what to do. It looks for a comforter to get under."

Dr. Elisseef and her colleagues seem to have discovered just the right type of "comforter" under which endogenous adult stem cells can happily thrive and proliferate.

The U.S. company BioTime Inc. and the the Hong Kong company Nashan Memorial Medical Institute today announced the collabortive formation of a new BioTime subsidiary.

The new company, to be known as BioTime Asia, will be focused on the development and commercialization throughout China and other Asian nations of stem cell products for occular, hematologic and musculoskeletal treatments. Dr. Lu Daopei, who pioneered China’s first successful adult stem cell transplant from bone marrow, will advise BioTime Asia with the management of clinical trials. It is expected, however, that the emphasis of BioTime Asia’s future clinical trials throughout the Far East will be on human embryonic, not adult, stem cells.

Based in Alameda, California, BioTime is engaged in a number of various medical specializations which include the development of artificial blood plasma solutions for trauma and surgery, in addition to the R&D of low temperature "suspended animation" medicine, and, of course, ongoing embryonic stem cell research, for which the company is perhaps best known. Dr. Michael West, BioTime’s CEO, is also the founder of Geron which has frequently been in news headlines over the past year for its highly controversial human embryonic stem cell (hESC) clinical trials, which were brought to an abrupt halt before they even began, due to an FDA "hold" that was recently imposed. No doubt the decision to transfer hESC clinical trials outside of the U.S. to Asian countries – where regulatory agencies and laws are significantly different from those of the U.S. FDA – was an executive calculation not entirely uninfluenced by the recent FDA-imposed "hold" on Geron’s clinical trials.

Financial terms of the new agreement were not disclosed.

The U.S. company Stem Cell Therapy International Inc. (SCII) announced today a reorganization and stock purchase agreement with S. Korea’s leading stem cell company, Histostem. The agreement marks the first step in the completion of a merger between the two companies.

Following a finalization of the agreement, the U.S. operations of Histostem will be managed by AmStem International, a wholly owned subsidiary of SCII.

As reported in initial filings with the S.E.C. (Securities and Exchange Commission), SCII will acquire 90% of the issued and outstanding shares of Histostem in consideration for the issuance of 72.5 million shares of Histostem stock.

According to David Stark, president and CEO of SCII, the company is in the process of securing supply channels in order to strengthen cash flow, which include a worldwide distribution of already existing stem cell facial cream and cosmetics products.

As stated in the press release, "Additional revenue is expected from the development of proprietary technologies from Dr. Han Hoon, CEO of Histostem, who will be working together with AmStemm to bring new products to the U.S. and E.U. markets."

This merger announcement was not unexpected but in fact was a required condition of a litigation settlement to which both companies had previously agreed and which had been announced on September 10th of this year. (Please see the related news article on this website, entitled, "U.S. and S. Korean Stem Cell Companies Announce Litigation Settlement", dated September 10, 2009).

Based in Tampa, Florida, SCII is a regenerative medicine company that is "devoted to the treatment of patients with stem cell transplantation therapy as well as providing the supplies of biological solutions containing new lines of stem cell products," as described on their website. As further described on the company’s website, SCII uses a type of adult stem cell procedure which they refer to simply as "stem cell transplantation (SCT)", which uses exclusively adult stem cells and which, as they explain, "is a surgical procedure that has been used successfully for 70+ years as a treatment of many diseases for which modern medicine has had no therapy, or in which state-of-the-art therapies stopped being effective. A documented 5 million patients have been so treated worldwide to date, evidenced by over 120,000 publications in MEDLINE (see www.nlm.nih.gov) amongst others. SCT is approved for use by the German authorities and the EU."

AmStem International, a wholly owned subsidiary of SCII, is based in Northern California where it specializes in "biotherapeutic and cosmetic stem cell products".

Founded in 2000 and based in Seoul, S. Korea, Histostem houses the largest repository of cord blood stem cells in the world, from which the company has already treated more than 500 patients. The company currently has 56 full-time employees and 28 part-time employees, and an intellectual property portfolio that consists of 5 patents that have already been granted and 6 patent applications that are still pending.

Scientists at the University of Piitsburgh have announced today the awarding by NIH (the National Institutes of Health) of two separate grants totalling more than $5 million. One of the grants is for the study of embryonic stem cell differentiation, while the other is for investigating a new method of growing adult stem cells on lymph nodes.

Specifically, the $2.9 million, five-year "Transformative R01" grant was awarded to Dr. Eric Lagasse, professor of pathology at the University of Pittsburgh’s School of Medicine and a researcher at the McGowan Institute for Regenerative Medicine. Funding from T-R01 has been designated for the study of a novel method of "using the body’s many lymph nodes as sites for growing replacement cells for other tissues and organs, in essence using them as bioreactors to grow cells within the living body," as described in the press release.

The second grant, in the amount of $2.2 million and entitled "New Innovator", has been awarded to Dr. Ipsita Banerjee, professor of chemical and petroleum engineering and Pitt and also a researcher at McGowan. Funding from Dr. Banerjee’s "New Innovator" award has been designated to study exactly which chemical and molecular signals are involved in determining how embryonic stem cells differentiate.

As Dr. Lagasse explained, "Our regenerative medicine approach for healing damaged tissues and organs might not have moved forward without this new grant concept. This funding supports assessment and rapid translation from the bench to the bedside of nontraditional treatments."

As Dr. Banerjee added, "I want to take a completely different approach to addressing the complex process of cell development, which will potentially advance our understanding of regenerative medicine and stem cell bioengineering as a whole."

The two grants were presented as part of the 2009 NIH "Director’s High-Risk Research Awards", which are a cluster of five-year grants awarded by NIH. This year’s cluster of 115 grants constitute $348 million in total, which include 42 separate T-R01 Awards, 18 separate "Pioneer Awards", and 55 separate "New Innovator Awards" for early-stage investigators.

As described in the press release, "This marks the inaugural year for the T-R01 grants, which support innovative and high-risk projects that could profoundly impact biomedical research and medical treatment, and also is a record year for the number of New Innovator and Pioneer Awards bestowed. Fellow New Innovator and T-R01 recipients include researchers from the Cleveland Clinic, Columbia University, Duke University, Harvard University, Johns Hopkins University School of Medicine, Massachusetts General Hospital, the Massachusetts Institute of Technology, Mount Sinai School of Medicine, Stanford University, and the University of Pennsylvania."

Lava Man, the 8-year-old gelding who retired from racing last year, is now returning to racing and indefinitely postponing his retirement after showing significant improvement from autologous adult stem cell therapy.

Having dominated the California handicap division for the better part of 2 years, winning 7 Grade 1’s and earning $5.2 million in the process, Lava Man was forced into retirement last fall due to "declining form" which was caused by recurring ankle problems. Now, after having undergone several months of autologous adult stem cell therapy, the horse is showing improved physical condition, his ankle is no longer bothering him and he was able to return to the track two weeks ago for the first time in over a year.

Administered by Dr. Doug Herthel of Alamo Pintado Equine Medical Center, the monthly stem cell procedure was found to successfully regenerate cartilage in Lava Man’s ankle, thereby allowing him to begin light exercise in the spring and summer. According to the horse’s trainer, Doug O’Neill, "Training was part of the study, which we agreed to. He’s been in training for three months, and they have been raving about him." Prior to receiving the adult stem cell therapy, Lava Man was scheduled for retirement at Old Friends in Kentucky, but the retirement has now been postponed indefinitely due to the horse’s significant improvement and resumption of his racing career. Owners Steve Kenly and Jason Wood have confirmed that the horse is now noticeably ready and eager to return to racing. As Kenly stated, "He was telling us, don’t send me to Kentucky. This horse wants to train, probably more so than most horses."

Acquired by STD (Steve, Tracy and Dave Kenly) Racing Stable in August of 2004 for $50,000, Lava Man showed initial improvement with his new trainer O’Neill and went on to sweep the 2006 Grade 1 handicap races in California, which included the Santa Anita Handicap, the Hollywood Gold Cup, and the Pacific Classic at Del Mar. A 3-time winner of the Gold Cup, Lava Man last raced in July of 2008, returning to Hollywood Park in September of this year, and is now continuing to progress noticeably.

As Kenly explains, "We have his best interests in mind, and if he tells us anytime he doesn’t want to do this, that’s it," adding, "Either he competes at the highest level, or nothing."

According to O’Neill, if Lava Man is able to return to a full racing career such as that which he had previously enjoyed, then O’Neill would personally donate all of his trainer purse earnings to the racehorse retirement foundation CARMA.

The autologous adult stem cell therapy that Lava Man has been receiving would seem to indicate that the horse will not be ready for retirement for quite some time.

In a growing effort to increase public awareness of the importance of storing adult stem cells that are derived from umbilical cord blood, the Cord Blood Registry (CBR) of California has designed a web-based, online education program for the general public.

Results of recent data reflecting dismal public ignorance about stem cells were presented at an international meeting on stem cell science and policy, at which particular emphasis was given to a proprietary, web-based education system developed by the CBR which is specifically designed to help improve public awareness about adult stem cells in general, and about cord blood preservation options in particular. Although the term "stem cells" is commonly and casually thrown around by the general public on a routine basis, there are very few members of the nonscientific lay public who actually understand the scientific facts of stem cells. For example, despite continued efforts by government agencies, consumer advocacy groups and private industry to educate the public about the medical benefits of banking cord blood stem cells, 9 out of 10 expectant mothers still do not bank their child’s umbilical cord blood at all. This web-based education system marks an important step in addressing and hopefully correcting this growing problem.

In a survey of people who had completed the education program, 93% indicated that the program had improved their understanding of stem cells, while 95% indicated that they were highly satisfied with the overall program. Additionally, the CBR invited physicians, nurses and other healthcare providers to provide feedback on the program, and reviews have been submitted by nearly 7,000 individuals from these fields. According to Kelly Harkey, M.D., M.P.H., an obstetrician and gynecologist, "It’s great to finally have an up-to-date, easy-to-understand resource to direct my patients to as they are weighing their cord blood options. Because educating patients about cord blood is encouraged in my state, it’s nice that at the end of the program patients are able to confirm they’ve been educated, which ensures my practice is compliant with state legislation."

According to Heather Brown, vice president of scientific and medical affairs at the CBR, "The goal of this cord blood education program is to help physicians and other labor and delivery specialists provide expecting parents with scientifically accurate information in a compelling format, so they can make an informed choice about the options for preserving their newborn’s cord blood stem cells. This web-based system offers many advantages in that it is accessible at any time of day, it’s easily shared with spouses and other family members, and can provide documentation of the patient’s education and informed choice, especially where public policy encourages or requires education."

As early as 2005, the Institute of Medicine (IOM) had recommended that pregnant women should be educated early in their pregnancies on the value of cord blood stem cells, in order to be able to make an informed decision about cord blood banking. Thus far, however, only 17 states have passed laws that implement the IOM guidelines on cord blood education.

Adult stem cells derived from umbilical cord blood are among some of the most versatile and potent of all types of stem cells, yet they lack the inherent risks and dangers that characterize embryonic stem cells and even iPS cells. Furthermore, umbilical cord blood stem cells have already accumulated a well documented clinical history, having been used in the treatment of nearly 80 different diseases to date.

The online program is divided into categories which include descriptions of cord blood stem cells as well as the collection and storage processes, the use of cord blood in current medical treatments, recent and ongoing developments in new therapies, and storage options that are available to expectant parents. Video segments accompany the content along with personal stories from familes who describe how the banking of their own cord blood has impacted their lives.

As the world’s largest stem cell bank, the Cord Blood Registry is focused on the collection, processing and cryopreservation of adult stem cells that are collected from the umbilical cord blood of healthy, full-term newborns. CBR is accredited by the AABB (the American Association of Blood Banks) and is the family cord blood bank most recommended by obstetricians. As described in their press release, "The company has been profitable and cash flow positive from operations on a cumulative basis since 1999. CBR has processed and stored cord blood units for more than 300,000 newborns from around the world and has released more client cord blood units for specific therapeutic use than any other family cord blood bank. CBR is the leader in research and development efforts in collaboration with the world’s leading clinical researchers focused on advancing regenerative medical therapies using a child’s own cord blood stem cells. The company continues to enhance its industry-leading technical innovations for stem cell collection, processing and storage that optimize quality and cell yield."

If the public is unaware of such facts, however, then it’s a bit difficult for anyone to benefit from the availability of such services.

Hopefully, the "Online Patient Education Center for Cord Blood Banking", which may be viewed at www.cordblood.com/learn, will bring these facts to the attention of more people.

As media outlets around the world reported this latest development in stem cell technology, the opening line of a U.S. News & World Report article began by posing the following question: "If you had a brain malady that could be treated with stem cells, how would you like them delivered – by having surgeons cut open your skull to implant the cells, or by snorting them like a nasal decongestant?"

Anticipating that the latter option might be more appealing than the former, a scientist at the University of Minnesota has shown that stem cells suspended in a fluid rapidly migrate to the brain when inhaled through the nose.

Dr. William Frey, adjunct professor of pharmaceutics in the College of Pharmacy at the University of Minnesota at St. Paul, in collaboration with colleagues in Tuebingen, Germany, has developed a new stem cell "delivery method" which has applications not only for stem cells but also for other therapeutic cells and drugs that cannot easily penetrate the blood-brain barrier.

The researchers demonstrated the method in an animal model in which mice were able to sniff small droplets of fluid in which adult stem cells that had been derived from rats were suspended. Within an hour, the rat stem cells were clearly detectable within the brains of the mice. In a second experiment, rats sniffed a fluid suspension of cells from human brain tumors, which were also found to penetrate the brains of the rats within an hour.

As Dr. Frey explains, "We proved you could noninvasively deliver stem cells to the brain from the nose. We’ve shown these cells reach the brain intact."

Dr. Frey and his collaborators have filed a patent application for the invention of this "stem cell delivery technology", which works by transmitting the stem cells via the olfactory nerves of the nose and the small holes that are found in the cribriform plate, which is a thin horizontal section of the skull at the base of the brain. The olfactory bulbs that lie just above the cribriform plate are, in fact, anatomical extensions of the brain.

When researchers combined the stem cells with the enzyme hyaluronidase, which makes connective tissue more permeable, the efficiency of the migrating stem cells increased. When the enzyme was not administered, only 584 stem cells out of 300,000 reached the olfactory bulbs, whereas that number tripled when the enzyme was administered. The enzyme did not improve the ability of the stem cells to reach the cerebral cortex or other areas of the brain, however.

According to Frey, "When you cut into the brain, that leads to an inflammatory response. We’re hoping this will help. We didn’t see evidence that intranasal stem cell treatment caused inflammation. Intranasal delivery of therapeutic cells could potentially benefit the treatment of head injury, stroke, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and so on. One of the best ways to treat patients may be with their own cells. For example, the patient’s own bone marrow-derived stem cells could be delivered to produce dopamine, the missing chemical messenger in Parkinson’s disease. Therefore, we are also looking into the use of antibiotics, anti-inflammatories, and immunosuppressants that may further facilitate the safe delivery of therapeutic cells."

The next step is to test the intranasal stem cell therapy in an animal model of Parkinson’s or other types of neurological diseases, testing not only for efficacy but also for safety, especially side effects such as inflammation, infection or immune rejection.

The U.S. company Neuralstem announced today that it has won approval from the FDA to begin clinical trials for the testing of its adult stem cell therapy as a treatment for ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig’s disease.

According to Neuralstem, Phase I of the clinical trial will involve injection of its proprietary adult stem cell product directly into the grey matter of the lumbar area of the spinal cord of human patients who are suffering with varying degrees of the disease. The target enrollment is twelve patients who will be given between 5 and 10 injections of Neuralstem’s patented adult stem cell product. Data from the trial are expected in approximately 2 years.

Dr. Eva Feldman, director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research and Discovery, will lead the trial. According to Dr. Feldman, "In work with animals, these spinal cord stem cells both protected at-risk motor neurons and made connections to the neurons controlling muscles. We don’t want to raise expectations unduly, but we believe these stem cells could produce similar results in patients with ALS."

It has been estimated that approximately 30,000 people suffer from ALS in the United States alone, with approximately 7,000 new cases diagnosed each year. Currently conventional medicine offers no known cure for ALS, which is a fatal disease characterized by progressive paralysis. With the advent of regenerative medicine, however, adult stem cells may prove to be the first actual therapy which not only reverses the course of the disease but which also regenerates damaged neurological tissue.

Although Neuralstem holds a number of patents for embryonic stem cell methods and processes in animal models, the company’s human stem cell product does not involve embryonic stem cells but instead is based exclusively upon adult stem cells that are derived from human adult CNS tissue.

Following today’s announcement of the FDA’s approval of the trial, Neuralstem’s stock increased 57%, or 21 cents, closing today at $2.08.

With corporate headquarters in Rockville, Maryland, Neuralstem was founded in 1996 by the current president and CEO, Richard Garr, J.D., and Merrill Solomon. As stated on their website, Neuralstem describes itself as "a biotherapeutics company utilizing its patented Human Neural Stem Cell technology", which "allows for the isolation of CNS (central nervous system) stem cells from tissue; the expansion in vitro of each cell up to a billion billion times (60 doublings), and the controlled differentiation of the cells into mature, physiologically relevant human neurons and glia."

(Please see the related news article on this website, entitled "Neuralstem Awarded Adult Stem Cell Patent", dated September 9, 2009).